How should kidney function be monitored during Abemaciclib therapy?

Serum creatinine at baseline and early; if elevated, obtain cystatin C / measured GFR before acting; Urinalysis if proteinuria/active sediment is suspected (to exclude true injury); Volume status and diarrhea severity (to catch superimposed prerenal AKI).

How can kidney injury from Abemaciclib be prevented?

Recognize the pattern to avoid unnecessary dose changes or imaging Use cystatin C / measured GFR when true function is in question Maintain hydration and manage diarrhea to prevent genuine prerenal AKI

Who is at higher risk of kidney injury from Abemaciclib?

Baseline reduced renal reserve (interpretation issue); Concomitant tubular-secretion inhibitors (e.g., trimethoprim, cimetidine); Diarrhea-related volume depletion (for true superimposed AKI).

Back to explorer

Printable monograph

CDK4/6 inhibitor

Abemaciclib

Verzenio · Abema

CDK4/6 inhibitor · approved 2017 · 8 citations · FAERS AKI reporting ROR 2.14 (95% CI 1.91–2.40, 306 AKI reports)

Up to date· through 2026

Fairly sourced5/9 · 5 signals

Met: 8 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 2y)
Met: Beyond single case reports
Not met: Peer-reviewed sources
Met: Landmark reference
Met: Current through 2026
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A CDK4/6 inhibitor that raises creatinine by blocking its tubular secretion — a 'pseudo-AKI' with intact true GFR.

MildCDK4/6 inhibitor

HR-positive, HER2-negative breast cancer (early and advanced)

§01

Signature kidney injury

Signature lesion

Pseudo-AKI

Representative incidence20%

A benign serum-creatinine rise occurs in roughly one-fifth of patients (~20% in a single-center series; a class effect across CDK4/6 inhibitors), almost always grade 1–2 and without true GFR loss. In a dedicated CDK4/6-inhibitor cohort, ~73% of creatinine rises were confirmed pseudo-AKI by cystatin C–based eGFR.Source: Ly et al., J Oncol Pharm Pract 2026 (~20% abemaciclib)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Creatinine rise appears early within the first weeks (median onset ~3 weeks), stays stable thereafter, and reverses on discontinuation.

Distilled from: “Early — within the first weeks (median onset ~3 weeks), stable thereafter, reversible on discontinuation.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Pseudo-AKI#1 · Signatureno population incidence denominator
Reversible serum creatinine rise ~15-40% over baseline from inhibition of tubular OCT2/MATE1/MATE2-K secretion; measured GFR and tubular-injury biomarkers (NGAL, KIM-1, cystatin C) unchanged PMID 30449032 (opens PubMed in a new tab)
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

20%incidence

SeverityMild

ReversibilityReversible

Evidence8 citations

Nephron map

Proximal TubuleBulk reabsorption + drug uptake (OCT2, OATs)

Pseudo-AKI

The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

§03

Kidney injury

Mechanism of kidney injury

Abemaciclib (and its active metabolites) inhibit the renal proximal-tubule transporters OCT2, MATE1 and MATE2-K that secrete creatinine into the tubular lumen, raising serum creatinine WITHOUT reducing actual glomerular filtration — a 'pseudo-AKI.' Measured GFR and other kidney biomarkers stay intact; cystatin C–based estimates (cystatin C is not secreted by these transporters) clarify true function. Genuine AKI (volume depletion from diarrhea, rare interstitial nephritis) remains possible and must not be missed.

Clinical presentation

Asymptomatic, early, mild creatinine elevation (cystatin C may also rise modestly but measured/true GFR is preserved); no proteinuria, electrolyte derangement or active sediment. Diarrhea is the dominant clinical toxicity and can cause superimposed prerenal azotemia.

Management

No intervention is needed for an isolated creatinine rise; do not reflexively reduce dose or stop the drug. Confirm with cystatin C or measured GFR. Remain alert that genuine AKI (prerenal from diarrhea, rare AIN) can still occur and warrants standard workup (urinalysis, volume assessment).Lesion-level management framework

Risk factors

Baseline reduced renal reserve (interpretation issue)
Concomitant tubular-secretion inhibitors (e.g., trimethoprim, cimetidine)
Diarrhea-related volume depletion (for true superimposed AKI)

Prevention

Recognize the pattern to avoid unnecessary dose changes or imaging
Use cystatin C / measured GFR when true function is in question
Maintain hydration and manage diarrhea to prevent genuine prerenal AKI

Anticancer mechanism· how it treats cancer

Cyclin-dependent kinase 4/6 inhibitor that prevents RB phosphorylation and arrests the G1–S cell-cycle transition, used with endocrine therapy in HR-positive, HER2-negative breast cancer (early and advanced); among CDK4/6 inhibitors it has the most continuous dosing and the strongest GI (diarrhea) signal.

Note · The creatinine rise reflects blocked tubular secretion (pseudo-AKI), not parenchymal injury; do not mistake it for true nephrotoxicity. Pharmacovigilance data nonetheless capture occasional true ATN/interstitial nephritis, so 'pseudo-AKI' is the rule, not an absolute.

§04

Clinical depth

Renal dose adjustment

No dose adjustment for mild-to-moderate renal impairment; severe renal impairment and ESKD are not well characterized (hepatic, not renal, impairment drives reduction). Critically, the drug-induced serum-creatinine rise should NOT trigger dose reduction by itself — verify true GFR first.

Dialyzability & ESKD dosing

Not characterized; abemaciclib is highly protein-bound and hepatically (CYP3A4) metabolized, so it is unlikely to be appreciably dialyzed. No ESKD dosing guidance exists.

Differential diagnosis

Pseudo-AKI (creatinine rise, normal cystatin C–based/measured GFR, bland urine, early/stable) vs true AKI: prerenal azotemia from diarrhea (responds to volume) or, rarely, acute interstitial nephritis/ATN (active sediment, progressive). Cystatin C and urinalysis are the discriminators.

Monitoring

Serum creatinine at baseline and early; if elevated, obtain cystatin C / measured GFR before acting
Urinalysis if proteinuria/active sediment is suspected (to exclude true injury)
Volume status and diarrhea severity (to catch superimposed prerenal AKI)

Key trials & series

Ly et al., J Oncol Pharm Pract 2026 — single-center series quantifying pseudo-creatinine elevation as a CDK4/6-inhibitor class effect (~20% abemaciclib)
Buijs et al., Br J Cancer 2025 — cohort confirming ~73% of CDK4/6-inhibitor creatinine rises are pseudo-AKI by cystatin C
monarchE / MONARCH registrational programs — established the abemaciclib creatinine-elevation signal

Clinical pearls

Abemaciclib raises creatinine by blocking OCT2/MATE-mediated tubular secretion — it is pseudo-AKI; confirm with cystatin C and do NOT reflexively cut the dose.
Other renally cleared co-medications dosed off this inflated creatinine may be under-dosed — use measured GFR for those.
Pseudo-AKI is the rule but not absolute: diarrhea can cause real prerenal AKI and rare true intrinsic injury occurs — keep checking the urine and volume status.

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2024–2026 · 7 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 1

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedCase report: A case of pseudo-acute kidney injury due to cyclin-dependent kinase inhibitor.Errabelli P et al. · Front Nephrol 2024 · PMID 38915820Documents abemaciclib-induced pseudo-AKI where creatinine rose due to blocked tubular secretion while cystatin C-based eGFR confirmed preserved true kidney function.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Jul 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr ≥30-89 mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr <30 mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown [see Clinical Pharmacology ( 12.3 )] .

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 19,870 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Acute Tubular Necrosis

ROR 3.1295% CI 2.17–4.50· 29 reports

Electrolyte Disturbance

ROR 1.2795% CI 1.12–1.45· 230 reports

FAERS outcomes & reporting trend· 7.2% of reports w/ death · 21.4% w/ hospitalization

7.2%

Reported with a death outcome

1,432 of 19,870 reports

21.4%

Reported with hospitalization

4,247 of 19,870 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 19,870 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.1495% CI 1.91–2.40· 306 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Renal & urinary

Blood Creatinine Increased424

Gastrointestinal

Diarrhoea6,094Nausea2,124Vomiting1,119Constipation697Abdominal Pain Upper676

General / constitutional

Fatigue2,551Asthenia863Pain537Weight Decreased492

Blood & lymphatic

White Blood Cell Count Decreased712Anaemia692Neutropenia635Myelosuppression530

Metabolic & electrolyte

Decreased Appetite952Dehydration543

Nervous system

Headache566Dizziness472

Skin

Alopecia585Rash401

Musculoskeletal

Arthralgia562

Respiratory

Dyspnoea547

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Abemaciclib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Capmatinib

Tabrecta · MET inhibitor

Profile

Reversible creatinine rise and edema.

PSEUDOPRE

Mild#1 · 89% phenotype match

Tepotinib

Tepmetko · MET inhibitor

Profile

Creatinine rise and peripheral edema.

PSEUDOPRE

Mild#2 · 89% phenotype match

Vorasidenib

Voranigo · Mutant IDH1/2 inhibitor

Profile

A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.

PSEUDOPRE

Mild#3 · 86% phenotype match

Imlunestrant

Inluriyo · Oral selective estrogen-receptor degrader (SERD)

Profile

2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.

PSEUDOPRE

Mild#4 · 86% phenotype match

Zongertinib

Hernexeos · HER2 TKI

Profile

HER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.

PSEUDOPRE

Mild#5 · 86% phenotype match

Alectinib

Alecensa · ALK TKI

Profile

Creatinine rise via reduced tubular secretion.

PSEUDOPRE

Mild#6 · 78% phenotype match

Compare Abemaciclib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across CDK4/6 inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1PalbociclibPSEUDO — Pseudo-AKIMild
2Abemaciclib· this agentPSEUDO — Pseudo-AKIFAERS AKIMild
3RibociclibPSEUDO — Pseudo-AKIFAERS AKIMild

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.